"10.1371_journal.pone.0035821","plos one","2012-05-01T00:00:00Z","Gordana D Vitaliano; Franco Vitaliano; Jose D Rios; Perry F Renshaw; Martin H Teicher","Laboratory of Developmental Psychopharmacology, Brain Imaging Center, Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, Massachusetts, United States of America; VXM, Boston, Massachusetts, United States of America; The Brain Institute, University of Utah School of Medicine, Salt Lake City, Utah, United States of America","Conceived and designed the experiments: GV FV MT. Performed the experiments: GV FV JR. Analyzed the data: GV MT JR. Contributed reagents/materials/analysis tools: GV PR MT. Wrote the paper: GV FV PR MT.","Gordana D. Vitaliano, Franco Vitaliano, and Perry F. Renshaw have an ownership interest in ExQor Technologies Inc., and stand to benefit financially if this technology is commercially adopted. ExQor Technologies owns patent rights to the clathrin protein nanotechnology (patents #7216038,#7219017, #7219018, #7393924). There are currently no products in development or marketed products related to this research. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","05","Gordana D Vitaliano","GDV",5,TRUE,3,3,3,4,TRUE,TRUE,FALSE,0,NA,FALSE
